Request Deal Involvement
Sumitovant Biopharma completed the acquisition of the remaining shares in Myovant Sciences for $1.7bn.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
financial advisors
JP Morgan
legal advisors
Sullivan & Cromwell
legal advisors to financial advisors
Latham & Watkins
legal advisors
Skadden Arps Slate Meagher & Flom
financial advisors
Goldman Sachs
legal advisors to financial advisors
Freshfields Bruckhaus Deringer
or
Principals
bidder
SUMITOVANT BIOPHARMA
target
MYOVANT SCIENCES
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite